Autologous natural killer cell therapy
1 paper studies it3 findings
Across all fields, 1 paper: 1 trial in people
- 1 lab in 1 country
- Funder: National Natural Science Foundation of China
- Human trial1
Outcomes
3Senescence-associated secretory phenotype (SASP)
downin humans1
1 study
Senescence-associated secretory phenotype (SASP)
downin humans1
Autologous natural killer cell therapy decreases senescence-associated secretory phenotype (SASP) in humans.
“Moreover, SASP-related factors including IL-6, IL-8, IL-1α, IL-17, MIP-1α, MIP-1β, and MMP1 were significantly decreased after NK cell infusion.”
Human trialhealthy participantsexpanded NK cellsserum4 weeksn = 32
Frontiers in immunology
Exhausted T cells
downin humans1
1 study
Exhausted T cells
downin humans1
Autologous natural killer cell therapy decreases exhausted T cells in humans.
“so did PD-1+ and TIM-3+ T cells. These changes were continuously observed for 4 weeks.”
Human trialhealthy participantsexpanded NK cellsperipheral blood4 weeksn = 32
Frontiers in immunology
Senescent T cells
downin humans1
1 study
Senescent T cells
downin humans1
Autologous natural killer cell therapy decreases senescent T cells in humans.
“After NK cell infusion, senescent CD28−, CD57+, CD28−CD57+, and CD28−KLRG1+ CD4+ and CD8+ T-cell populations decreased significantly”
Human trialhealthy participantsexpanded NK cellsperipheral blood4 weeksn = 32
Frontiers in immunology
Latest
Frontiers in Immunology
Characterization of age-related immune features after autologous NK cell infusion: Protocol for an open-label and randomized controlled trial
Randomized trial in 37 peopleBlood and immune system